Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 37 | 2024 | 356 | 5.170 |
Why?
|
| Brain Neoplasms | 37 | 2024 | 638 | 4.250 |
Why?
|
| Deep Brain Stimulation | 14 | 2023 | 49 | 2.710 |
Why?
|
| Parkinson Disease | 6 | 2024 | 87 | 1.290 |
Why?
|
| Meningioma | 6 | 2022 | 57 | 1.290 |
Why?
|
| Meningeal Neoplasms | 6 | 2022 | 49 | 1.260 |
Why?
|
| Alzheimer Disease | 6 | 2014 | 327 | 1.200 |
Why?
|
| Radiation Injuries | 3 | 2023 | 76 | 1.040 |
Why?
|
| Retrospective Studies | 36 | 2024 | 3510 | 1.010 |
Why?
|
| Treatment Outcome | 32 | 2023 | 3306 | 0.980 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 367 | 0.920 |
Why?
|
| Humans | 77 | 2024 | 32114 | 0.850 |
Why?
|
| Trigeminal Neuralgia | 3 | 2019 | 33 | 0.800 |
Why?
|
| Fornix, Brain | 4 | 2014 | 7 | 0.760 |
Why?
|
| Middle Aged | 48 | 2020 | 11839 | 0.740 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 78 | 0.720 |
Why?
|
| Brain | 6 | 2023 | 951 | 0.710 |
Why?
|
| Neurons | 2 | 2014 | 410 | 0.700 |
Why?
|
| Laser Therapy | 5 | 2023 | 55 | 0.690 |
Why?
|
| Salvage Therapy | 11 | 2020 | 134 | 0.680 |
Why?
|
| Glioblastoma | 5 | 2020 | 156 | 0.640 |
Why?
|
| Male | 50 | 2023 | 19217 | 0.630 |
Why?
|
| Female | 50 | 2023 | 20015 | 0.620 |
Why?
|
| Adult | 32 | 2020 | 9380 | 0.610 |
Why?
|
| Aged | 38 | 2023 | 10314 | 0.600 |
Why?
|
| Dopamine | 6 | 2024 | 232 | 0.570 |
Why?
|
| Emotions | 3 | 2024 | 58 | 0.540 |
Why?
|
| Gyrus Cinguli | 2 | 2013 | 22 | 0.540 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2023 | 7 | 0.530 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 93 | 0.530 |
Why?
|
| Depressive Disorder, Major | 2 | 2013 | 42 | 0.520 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2014 | 7 | 0.490 |
Why?
|
| Electric Stimulation Therapy | 1 | 2014 | 14 | 0.490 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 126 | 0.480 |
Why?
|
| Basal Ganglia | 1 | 2014 | 15 | 0.480 |
Why?
|
| Thalamus | 1 | 2014 | 33 | 0.470 |
Why?
|
| Memory | 2 | 2012 | 190 | 0.470 |
Why?
|
| Neurosurgical Procedures | 4 | 2021 | 99 | 0.460 |
Why?
|
| Corpus Striatum | 3 | 2020 | 60 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 1328 | 0.450 |
Why?
|
| Memory Disorders | 2 | 2010 | 54 | 0.440 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 3990 | 0.440 |
Why?
|
| Hippocampus | 5 | 2018 | 171 | 0.430 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 71 | 0.430 |
Why?
|
| Glioma | 3 | 2021 | 136 | 0.430 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 2265 | 0.420 |
Why?
|
| Dementia | 1 | 2012 | 252 | 0.340 |
Why?
|
| Cognition Disorders | 1 | 2013 | 385 | 0.340 |
Why?
|
| Serotonin | 2 | 2020 | 38 | 0.330 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 317 | 0.330 |
Why?
|
| Necrosis | 3 | 2023 | 53 | 0.330 |
Why?
|
| Electrodes, Implanted | 3 | 2022 | 41 | 0.310 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 414 | 0.310 |
Why?
|
| Neoplasms | 4 | 2020 | 728 | 0.290 |
Why?
|
| Decision Making | 2 | 2020 | 195 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 40 | 0.280 |
Why?
|
| Reward | 4 | 2024 | 64 | 0.270 |
Why?
|
| Syringomyelia | 1 | 2006 | 3 | 0.270 |
Why?
|
| Glioma, Subependymal | 1 | 2005 | 2 | 0.270 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2005 | 5 | 0.260 |
Why?
|
| Spinal Injuries | 1 | 2006 | 20 | 0.260 |
Why?
|
| Melanoma | 5 | 2019 | 164 | 0.260 |
Why?
|
| Nomograms | 3 | 2015 | 32 | 0.260 |
Why?
|
| Prognosis | 9 | 2020 | 1497 | 0.260 |
Why?
|
| Spinal Cord | 1 | 2006 | 130 | 0.250 |
Why?
|
| Multiple Sclerosis | 2 | 2019 | 59 | 0.240 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 114 | 0.240 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 22 | 0.240 |
Why?
|
| Punishment | 1 | 2023 | 3 | 0.230 |
Why?
|
| Kidney Neoplasms | 2 | 2024 | 201 | 0.220 |
Why?
|
| Voice Disorders | 1 | 2023 | 5 | 0.220 |
Why?
|
| Essential Tremor | 1 | 2023 | 12 | 0.220 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 94 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2018 | 780 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 34 | 0.210 |
Why?
|
| Epilepsy | 1 | 2023 | 82 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2019 | 1817 | 0.200 |
Why?
|
| Young Adult | 10 | 2020 | 2665 | 0.200 |
Why?
|
| Alcoholism | 1 | 2023 | 101 | 0.200 |
Why?
|
| Hypothalamus | 2 | 2012 | 17 | 0.200 |
Why?
|
| Combined Modality Therapy | 6 | 2022 | 560 | 0.190 |
Why?
|
| Brain Edema | 2 | 2014 | 15 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 101 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 130 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2018 | 82 | 0.180 |
Why?
|
| Sulfones | 1 | 2020 | 21 | 0.180 |
Why?
|
| Genomics | 2 | 2018 | 85 | 0.180 |
Why?
|
| Indans | 1 | 2020 | 31 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 46 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 220 | 0.170 |
Why?
|
| Time Factors | 5 | 2017 | 2151 | 0.170 |
Why?
|
| Carcinoma | 1 | 2020 | 91 | 0.170 |
Why?
|
| Visual Perception | 1 | 2020 | 116 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2020 | 483 | 0.160 |
Why?
|
| Survival Rate | 5 | 2020 | 877 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 100 | 0.160 |
Why?
|
| Astrocytoma | 1 | 2018 | 29 | 0.160 |
Why?
|
| Adolescent | 8 | 2020 | 3568 | 0.160 |
Why?
|
| Feedback, Psychological | 1 | 2018 | 6 | 0.150 |
Why?
|
| Mental Recall | 1 | 2018 | 51 | 0.150 |
Why?
|
| Recurrence | 2 | 2015 | 263 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 60 | 0.150 |
Why?
|
| Disease Progression | 4 | 2018 | 594 | 0.150 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 99 | 0.150 |
Why?
|
| Tremor | 2 | 2023 | 11 | 0.150 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.140 |
Why?
|
| Medicare | 1 | 2018 | 206 | 0.140 |
Why?
|
| Seizures | 3 | 2023 | 64 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2020 | 682 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 31 | 0.140 |
Why?
|
| Temporal Lobe | 1 | 2016 | 30 | 0.140 |
Why?
|
| Hypesthesia | 1 | 2015 | 9 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 765 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2020 | 162 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 192 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 13 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 608 | 0.130 |
Why?
|
| Hyperthermia, Induced | 2 | 2016 | 243 | 0.120 |
Why?
|
| Neurofibromatosis 2 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Carmustine | 1 | 2015 | 8 | 0.120 |
Why?
|
| Atrophy | 1 | 2014 | 46 | 0.120 |
Why?
|
| Reoperation | 1 | 2015 | 226 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2015 | 87 | 0.120 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.120 |
Why?
|
| Levodopa | 1 | 2014 | 14 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 308 | 0.120 |
Why?
|
| Incidence | 4 | 2020 | 1199 | 0.120 |
Why?
|
| Ecchymosis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Skull Base | 1 | 2013 | 4 | 0.110 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.110 |
Why?
|
| Orbital Diseases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Skull Fractures | 1 | 2013 | 17 | 0.110 |
Why?
|
| Neural Pathways | 2 | 2010 | 94 | 0.110 |
Why?
|
| Models, Neurological | 1 | 2014 | 117 | 0.110 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.110 |
Why?
|
| Brain Mapping | 2 | 2012 | 178 | 0.110 |
Why?
|
| Pain | 1 | 2015 | 288 | 0.110 |
Why?
|
| Craniocerebral Trauma | 1 | 2013 | 56 | 0.110 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.110 |
Why?
|
| Affect | 1 | 2013 | 70 | 0.110 |
Why?
|
| Subthalamic Nucleus | 1 | 2012 | 13 | 0.110 |
Why?
|
| Smoking | 1 | 2017 | 528 | 0.110 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 371 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.110 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2012 | 1 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2014 | 350 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2024 | 81 | 0.100 |
Why?
|
| Transients and Migrants | 1 | 2016 | 297 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 753 | 0.100 |
Why?
|
| Craniotomy | 2 | 2017 | 46 | 0.100 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 101 | 0.100 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2010 | 2 | 0.090 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2010 | 1 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2010 | 36 | 0.090 |
Why?
|
| Child | 4 | 2020 | 2442 | 0.090 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 31 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 97 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2010 | 73 | 0.090 |
Why?
|
| Radiation Dosage | 2 | 2020 | 84 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 163 | 0.080 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 2283 | 0.080 |
Why?
|
| Risk Factors | 4 | 2019 | 3880 | 0.080 |
Why?
|
| Ablation Techniques | 2 | 2018 | 25 | 0.080 |
Why?
|
| Amygdala | 2 | 2019 | 61 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 355 | 0.070 |
Why?
|
| Pedunculopontine Tegmental Nucleus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2007 | 26 | 0.070 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2005 | 4 | 0.070 |
Why?
|
| Stereotaxic Techniques | 2 | 2016 | 23 | 0.070 |
Why?
|
| Headache | 1 | 2005 | 75 | 0.060 |
Why?
|
| Animals | 4 | 2023 | 7542 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 946 | 0.060 |
Why?
|
| Mammals | 1 | 2023 | 12 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2015 | 141 | 0.060 |
Why?
|
| Lasers | 1 | 2023 | 21 | 0.060 |
Why?
|
| Motivation | 1 | 2024 | 113 | 0.050 |
Why?
|
| Immersion | 1 | 2022 | 3 | 0.050 |
Why?
|
| Learning | 1 | 2023 | 79 | 0.050 |
Why?
|
| Gelatin | 1 | 2022 | 29 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2022 | 26 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 52 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 684 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 82 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 121 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 94 | 0.050 |
Why?
|
| Collagen | 1 | 2022 | 225 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 163 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2020 | 158 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 291 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 169 | 0.040 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 321 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 415 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 726 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 604 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 2018 | 19 | 0.040 |
Why?
|
| Neuronavigation | 1 | 2017 | 8 | 0.040 |
Why?
|
| Hearing Tests | 1 | 2017 | 13 | 0.040 |
Why?
|
| Brain Death | 1 | 2017 | 26 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 53 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2016 | 10 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2022 | 656 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2017 | 149 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 59 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 71 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 126 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 41 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1270 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 259 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2015 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 464 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 81 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 71 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 58 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 2484 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 236 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 218 | 0.030 |
Why?
|
| Facial Pain | 1 | 2014 | 21 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 56 | 0.030 |
Why?
|
| Glucose | 1 | 2014 | 174 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 898 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 186 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 26 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 178 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 989 | 0.020 |
Why?
|
| North Carolina | 1 | 2016 | 1538 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2010 | 79 | 0.020 |
Why?
|
| United States | 1 | 2018 | 3976 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 474 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 919 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 556 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 743 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1596 | 0.020 |
Why?
|